02:31 , Mar 15, 2019 |  BC Innovations  |  Product Development

The microbiome universe in two maps

In its “big bang” over the last decade, the universe of microbiome therapeutics has expanded far beyond its origins of fecal transplants, used primarily for C. difficile . Mapping biotech activity reveals a broadening range...
17:31 , Mar 8, 2019 |  BC Week In Review  |  Company News

Deep Lens, Worldwide Clinical Trials partner to increase patient recruitment

Worldwide Clinical Trials will use Deep Lens' digital pathology platform VIPER -- Virtual Imaging Pathology for Education and Research -- to accelerate cancer diagnoses and present patients with clearer and earlier treatment and clinical trial...
01:56 , Mar 8, 2019 |  BC Innovations  |  Targets & Mechanisms

Oral insulin innovation

While clinical data suggest an oral insulin product may finally be within reach, the technology struggles to compete with injectables on price and efficacy. A handful of academics and companies are pushing preclinical innovation in...
00:27 , Mar 8, 2019 |  BC Innovations  |  Targets & Mechanisms

Flipping the switch in immuno-oncology

Tumor myeloid cells are emerging as prime candidates for filling a hole in the immuno-oncology tool box, offering targets that can simultaneously release the brakes and rev up the gas in the immune system. As...
21:17 , Mar 7, 2019 |  BC Extra  |  Politics & Policy

FDA will not change legacy biologic names

FDA said it no longer intends to retrospectively modify the names of biologics approved without an agency-designated suffix, according to updated draft guidance on the naming of biologics released Thursday. Under the naming convention, FDA...
00:47 , Feb 23, 2019 |  BioCentury  |  Tools & Techniques

Modeling now for precision later

GNS Healthcare Inc. is building a platform that aims to make value-based payment models unnecessary by giving companies a way to know which patients will respond before they even launch the drug. While drug companies...
21:27 , Feb 22, 2019 |  BioCentury  |  Finance

Accessing Hong Kong

Leveraging its position in Hong Kong, the new CR-CP Life Science Fund aims to attract European and U.S. startups seeking growth opportunities in Hong Kong and China. The USD fund raised $150 million on Feb....
22:35 , Feb 21, 2019 |  BC Extra  |  Company News

JPM, Berkshire, Amazon venture to test how best to shake up benefits scheme

The ABC healthcare venture will test this year how changes in traditional healthcare could drive patient satisfaction, lower costs and improve value -- before it implements any strategy. Details on the secretive venture, launched last...
03:20 , Feb 16, 2019 |  BioCentury  |  Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
22:03 , Feb 15, 2019 |  BC Extra  |  Politics & Policy

NICE provides first scientific advice on patient preference

The National Institute for Health and Care Excellence said on Thursday that it provided its first scientific advice to Novartis AG (NYSE:NVS; SIX:NOVN) on the design of a patient preference study for chronic obstructive pulmonary...